{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T23:52:42Z","timestamp":1788652362397,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1053\/j.seminhematol.2013.03.005","type":"journal-article","created":{"date-parts":[[2013,5,10]],"date-time":"2013-05-10T00:06:23Z","timestamp":1368144383000},"page":"S18-S21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"S1","title":["Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia"],"prefix":"10.1053","volume":"50","author":[{"given":"Deborah","family":"Siegal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Crowther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Cuker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1053\/j.seminhematol.2013.03.005_bib1","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.03.005_bib2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ajh.20104","article-title":"Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies","volume":"76","author":"Aledort","year":"2004","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1053\/j.seminhematol.2013.03.005_bib3","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1172\/JCI26674","article-title":"The molecular mechanisms that control thrombopoiesis","volume":"115","author":"Kaushansky","year":"2005","journal-title":"J Clin Invest"},{"issue":"4-5","key":"10.1053\/j.seminhematol.2013.03.005_bib4","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.blre.2010.04.002","article-title":"Thrombopoietic agents","volume":"24","author":"Stasi","year":"2010","journal-title":"Blood Rev"},{"issue":"6","key":"10.1053\/j.seminhematol.2013.03.005_bib5","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1056\/NEJM199702063360603","article-title":"Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer","volume":"336","author":"Fanucchi","year":"1997","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.seminhematol.2013.03.005_bib6","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1182\/blood.V100.10.3457","article-title":"Recombinant human thrombopoietin: basic biology and evaluation of clinical studies","volume":"100","author":"Kuter","year":"2002","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2013.03.005_bib7","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood.V98.12.3241","article-title":"Thrombocytopenia caused by the development of antibodies to thrombopoietin","volume":"98","author":"Li","year":"2001","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2013.03.005_bib8","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.clpt.2004.08.010","article-title":"Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand","volume":"76","author":"Wang","year":"2004","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1053\/j.seminhematol.2013.03.005_bib9","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMct1014202","article-title":"Thrombopoietin-receptor agonists for primary immune thrombocytopenia","volume":"365","author":"Imbach","year":"2011","journal-title":"N Engl J Med"},{"issue":"9610","key":"10.1053\/j.seminhematol.2013.03.005_bib10","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1053\/j.seminhematol.2013.03.005_bib11","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2141.2008.07464.x","article-title":"Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials","volume":"144","author":"George","year":"2009","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2013.03.005_bib12","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/ajh.23163","article-title":"Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care","volume":"87","author":"Kuter","year":"2012","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2013.03.005_bib13","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1179\/102453311X13025568942005","article-title":"Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim","volume":"16","author":"Michel","year":"2011","journal-title":"Hematology"},{"issue":"21","key":"10.1053\/j.seminhematol.2013.03.005_bib14","first-page":"68","article-title":"Long-term efficacy and safety of romiplostim treatment of adult patients with chronic immune thrombocytopenia (ITP): final report from an open-label extension study","volume":"116","author":"Kuter","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"20","key":"10.1053\/j.seminhematol.2013.03.005_bib15","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1002625","article-title":"Romiplostim or standard of care in patients with immune thrombocytopenia","volume":"363","author":"Kuter","year":"2010","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1053\/j.seminhematol.2013.03.005_bib16","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.1182\/blood-2011-03-340166","article-title":"Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program","volume":"118","author":"Khellaf","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2013.03.005_bib17","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/stemcells.2008-0366","article-title":"Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist","volume":"27","author":"Erickson-Miller","year":"2009","journal-title":"Stem Cells"},{"issue":"1","key":"10.1053\/j.seminhematol.2013.03.005_bib18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.exphem.2004.09.006","article-title":"Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist","volume":"33","author":"Erickson-Miller","year":"2005","journal-title":"Exp Hematol"},{"issue":"11","key":"10.1053\/j.seminhematol.2013.03.005_bib19","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1182\/blood-2006-11-057968","article-title":"Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist","volume":"109","author":"Jenkins","year":"2007","journal-title":"Blood"},{"issue":"22","key":"10.1053\/j.seminhematol.2013.03.005_bib20","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa073275","article-title":"Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura","volume":"357","author":"Bussel","year":"2007","journal-title":"N Engl J Med"},{"issue":"9664","key":"10.1053\/j.seminhematol.2013.03.005_bib21","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(09)60402-5","article-title":"Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial","volume":"373","author":"Bussel","year":"2009","journal-title":"Lancet"},{"issue":"9763","key":"10.1053\/j.seminhematol.2013.03.005_bib22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","article-title":"Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study","volume":"377","author":"Cheng","year":"2011","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2013.03.005_bib23","unstructured":"Nplate (romiplostim) prescribing information. (Accessed at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125268s077lbl.pdf on Apr 25, 2012."},{"key":"10.1053\/j.seminhematol.2013.03.005_bib24","unstructured":"Promacta (eltrombopag) prescribing information. (Accessed at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/022291s006lbl.pdf on Apr 25, 2012."},{"issue":"10","key":"10.1053\/j.seminhematol.2013.03.005_bib25","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood-2008-04-150078","article-title":"Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP","volume":"113","author":"Bussel","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2013.03.005_bib26","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/j.1538-7836.2010.03830.x","article-title":"Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP)","volume":"8","author":"Gernsheimer","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"21","key":"10.1053\/j.seminhematol.2013.03.005_bib27","first-page":"67","article-title":"EXTEND study update: safety and efficacy of eltrombopag in adults with chronic immune thrombocytopenia (ITP) from June 2006 to February 2010","volume":"116","author":"Saleh","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"5","key":"10.1053\/j.seminhematol.2013.03.005_bib28","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/PAT.0b013e328348fecc","article-title":"Reversible bone marrow reticulin fibrosis as a side effect of romiplostim therapy for the treatment of chronic refractory immune thrombocytopenia","volume":"43","author":"Leung","year":"2011","journal-title":"Pathology"},{"issue":"2","key":"10.1053\/j.seminhematol.2013.03.005_bib29","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1365-2141.2011.08845.x","article-title":"Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents","volume":"155","author":"Ghanima","year":"2011","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1053\/j.seminhematol.2013.03.005_bib30","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1182\/blood-2009-05-224766","article-title":"Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim","volume":"114","author":"Kuter","year":"2009","journal-title":"Blood"},{"issue":"21","key":"10.1053\/j.seminhematol.2013.03.005_bib31","first-page":"528","article-title":"Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenic purpura (ITP) treated with eltrombopag\u2014data from the EXTEND study","volume":"118","author":"Brynes","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"2","key":"10.1053\/j.seminhematol.2013.03.005_bib32","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia","volume":"115","author":"Provan","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2013.03.005_bib33","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/j.1538-7836.2012.04876.x","article-title":"Contemporary management of primary immune thrombocytopenia in adults","volume":"10","author":"Lakshmanan","year":"2012","journal-title":"J Thromb Haemost"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196313000243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196313000243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:23:42Z","timestamp":1758522222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196313000243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":33,"alternative-id":["S0037196313000243"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2013.03.005","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2013.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}